Diagnocure Announces Resignation of CFO

Transition plan in place

QUEBEC CITY, Oct. 1, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation") announced today that Ms. Chantal Miklosi has resigned her position as Chief Financial Officer of the Corporation effective October 11^th. She will leave to pursue other career opportunities. Dr. Yves Fradet, President and Chief Medical Officer, supported by Mr. Richard Bordeleau, Senior Advisor, will maintain contact with investors and the general public. Mr. Frédéric Boivin, Senior Director, who has served in finances and administration for 12 years, will oversee financial matters. Ms. Danielle Allard, Senior Director, Corporate Affairs will continue to be responsible for all filings to regulatory agencies.

Dr. Yves Fradet, President and Chief Medical Officer said, "I want to thank Chantal for her important contributions to the Corporation during her tenure as Chief Financial Officer. She played an instrumental role in negotiating and closing all of DiagnoCure's recent business arrangements. We wish Chantal well in her new endeavors. As communicated recently, the DiagnoCure team will continue working on short-term initiatives aimed at increasing shareholder value and exploring all opportunities to enhance longer-term prospects for the Corporation."

About DiagnoCure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. Previstage^TM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States. For more information, please visit www.diagnocure.com.

Forward‐looking statements

This release may contain forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. Forward-looking statements can be identified by the use of the conditional or forward-looking terminology such as "anticipates", "assumes", "believes", "estimates", "expects", "intend", "may", "plans", "projects", "should", "will", or the negative thereof or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. All such forward-looking statements are made pursuant to the "safe-harbour" provisions of applicable Canadian securities laws. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Corporation's current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Corporation's business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes and that they should not place undue reliance on these forward‐looking statements. For instance, any forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues, including those related to PROGENSA® PCA3, are based on management expectations and such outcome may vary materially depending on global political and economic conditions, dependence on collaboration partners, uncertainty of healthcare reimbursement, and marketing and distribution challenges. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.

SOURCE DiagnoCure inc.